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Introduction
Th  e development of chemotherapy resistance continues 
to be the main problem in the treatment of cancer 
patients. Newer agents, whether chemotherapeutic or 
targeted, are constantly being developed. Although most 
anticancer therapies will alter tumor growth, in most 
cases the eﬀ   ect is not long lasting and failure of 
anthracyclines and taxanes impact the survival of breast 
cancer patients. Consequently, there is a signiﬁ  cant need 
for new agents with low susceptibility to common drug 
resistance mechanisms in order to improve response 
rates and potentially extend survival.
Approximately 30% of the women diagnosed with 
early-stage disease in turn progress to metastatic breast 
cancer (MBC), for which therapeutic options are limited 
[1]. After treatment with anthracycline or taxane-based 
[2] chemotherapy, options are limited as responses are 
generally low. Response rates range from 30% to 70% but 
the responses are often not durable, with a time to 
progression of 6 to 10 months [1,3]. Patients with 
progression or resistance may be adminis  tered capecita-
bine, gemcitabine, vinorelbine, or albumin-bound pacli-
taxel, with capecitabine being the only one approved by 
the US Food and Drug Administration (FDA) after 
anthracyclines and taxanes [4,5]. Response rates in this 
setting tend to be low (20 to 30%); the median duration of 
responses is <6 months [6] and the results do not always 
translate into improved long-term outcomes.
Resistance to chemotherapy can occur prior to drug 
treatment (primary or innate resistance) or may develop 
over time following exposure (acquired resistance) [7]. 
Patients with breast cancer who are treated with an 
anthracycline and/or a taxane commonly develop resis-
tance to one or both of the drugs. In some patients, 
prolonged exposure to a single chemotherapeutic agent 
may lead to the development of resistance to multiple 
other structurally unrelated compounds, known as cross-
resistance or multidrug resistance (MDR). In primary 
resistance, MDR can occur without prior exposure to 
chemotherapy.
Once resistance to taxanes or anthracyclines occurs, 
few treatment options exist. Most breast cancer patients 
with resistant or refractory disease are treated with 
capecitabine as a single agent or in combination. 
Approxi  mately 75% of patients treated with capecitabine 
do not respond, and many responders eventually become 
resistant [8-10]. Other chemotherapeutics that are used 
for the treatment of MBC resistant to anthracyclines, 
taxanes, and capecitabine include gemcitabine and 
vinorelbine [11]. Response rates with these agents in 
Abstract
Resistance to chemotherapy is a major obstacle to the 
eff  ective treatment of many tumor types. Although 
many anticancer therapies can alter tumor growth, in 
most cases the eff  ect is not long lasting. Consequently, 
there is a signifi  cant need for new agents with low 
susceptibility to common drug resistance mechanisms 
in order to improve response rates and potentially 
extend survival. Approximately 30% of the women 
diagnosed with early-stage disease in turn progress to 
metastatic breast cancer, for which therapeutic options 
are limited. Current recommendations for fi  rst-line 
chemotherapy include anthracycline-based regimens 
and taxanes (paclitaxel and docetaxel). They typically 
give response rates of 30 to 70% but the responses 
are often not durable, with a time to progression of 
6 to 10 months. Patients with progression or resistance 
may be administered capecitabine, gemcitabine, 
vinorelbine, albumin-bound paclitaxel, or ixabepilone, 
while other drugs are being evaluated. Response 
rates in this setting tend to be low (20 to 30%); the 
median duration of responses is <6 months and the 
results do not always translate into improved long-
term outcomes. The present article reviews treatment 
options in taxane-resistant metastatic breast cancer 
and the role of ixabepilone in this setting.
© 2010 BioMed Central Ltd
Chemotherapy resistance in metastatic breast 
cancer: the evolving role of ixabepilone
Edgardo Rivera1* and Henry Gomez2
REVIEW
*Correspondence: erivera1@tmhs.org
1The Methodist Hospital/Weill Cornell University, 6550 Fannin Street, SM701, 
Houston, TX 77030, USA
Full list of author information is available at the end of the article
Rivera and Gomez Breast Cancer Research 2010, 12(Suppl 2):S2
http://breast-cancer-research.com/supplements/12/S2/S2
© 2010 BioMed Central Ltdanthracycline-refractory and taxane-refractory disease 
range from 16 to 25%, and survival is limited [1,12-14]. 
Resistance is also an issue for women who have human 
epidermal growth factor receptor-2 (HER2)-positive 
breast cancer. Th  e  HER2-speciﬁ  c inhibitors trastuzumab 
and lapatinib have demonstrated eﬃ   cacy in the meta-
static setting [15-17]. Most MBC patients treated with 
trastuzumab, however, develop resistance within 1 year 
[18].
Recent research has suggested potential novel 
therapeutic targets for drug-resistant MBC. Tumor stem 
cells have been identiﬁ  ed in many malignancies, includ-
ing breast cancer [19,20]. Accumulation of drug resis-
tance mutations in stem cells, coupled with their high-
level expression of the ATP-binding cassette (ABC) drug 
transporters, noncycling state, and enhanced DNA 
repair, may contribute to the generation of resistance to 
chemotherapy [21]. Th  e high proliferative potential of 
such cells could therefore result in the rapid regrowth of 
resistant tumors. Studies are currently investigating the 
potential to speciﬁ  cally target breast cancer stem cells 
using agents that block drug transport or other small-
molecule inhibitors [20]. It has been proposed that drug 
resistance may develop early in tumorigenesis, prior to 
the onset of well-recognized genotypic changes. Target-
ing initial events in tumorigenesis may suppress the early 
development of drug resistance. Novel microtubule 
inhibitors, such as ixabepilone, show signiﬁ  cant activity 
in MBC and do not exhibit cross-resistance with taxanes 
or other commonly used chemotherapies; they are 
therefore potential candidates for the treatment of drug-
resistant diseases [22,23].
Th   e aim of the present article is to review the current 
therapeutic alternatives to treat MBC resistant to taxanes.
Molecular mechanisms of drug resistance
Chemotherapy resistance can arise through a number of 
diﬀ   erent mechanisms, including alterations in drug 
pharma  co  kinetics and metabolism, modiﬁ  cation of drug 
target expression or function (for example, gene ampli-
ﬁ   cation/overexpression, overexpression of β-tubulin 
isotypes, and topoisomerase II mutations), drug com  part-
mentalization in cellular organelles, altered repair of drug-
induced DNA damage, changes in apop  totic signaling 
pathways (for example, mutated p53), and expres  sion of 
proteins directly aﬀ  ecting cellular drug transport (eﬄ   ux 
pumps) (Table 1) [24,25]. Th   e hetero  geneity of cancer cells, 
coupled with their high mutation rate, contributes to rapid 
selection for drug-resistant clones. Th  e  best  characterized 
of these resistance mecha  nisms are drug eﬄ   ux pathways.
Many transport-mediated drug resistance mechanisms 
involve the ABC membrane transporter family. Th  e  most 
well-characterized examples of these drug eﬄ   ux 
transporters include the P-glycoprotein (P-gp) pump, 
multidrug-resistant protein-1 (MRP1), and breast cancer 
resistance protein. Th  ese energy-dependent proteins 
actively pump drugs such as chemotherapeutics out of 
the cells, thereby reducing their intracellular drug 
concentration and decreasing the cytotoxicity [7].
Drug transport/sequestration
Expression of pumps such as P-gp or MRP1 gives tumor 
cells the ability to evade the chemotherapy drugs, and 
their role has been evaluated in breast cancer.
P-gp is a 170 kDa glycoprotein encoded by the MDR1 
gene. Th   is ATP-dependent membrane transporter pumps 
a diverse array of chemotherapeutics across the cell 
membrane and out of the cells, including anthracyclines, 
taxanes, vinca alkaloids, epipodophyllotoxins, and anti-
folates. Th  e normal physiologic role of P-gp is still 
unknown, but it may serve to protect normal tissues from 
toxic products and xenobiotics [24]. P-gp expression 
varies widely in breast cancer, according to the assay 
method used. A meta-analysis revealed that this protein 
is expressed in approximately 40% of all breast carci-
nomas [26], although another study reported values as 
high as 66% [27]. Exposure to selected chemotherapeutics 
may increase P-gp expression in breast cancer, as seen in 
some patients following neoadjuvant chemotherapy 
[28,29]. In the meta-analysis, prior chemotherapy or 
hormonal therapy was found to enhance the proportion 
of P-gp-positive tumors by nearly 1.8-fold. Th  is  increased 
P-gp expression was associated with a threefold increased 
risk of failure to respond to chemotherapy [26]. Th  e 
expression of P-gp, therefore, correlated with a poorer 
outcome in this and other studies [30,31], although other 
reports did not ﬁ  nd such an association [27,32].
MRP1 has been also implicated in MDR. MRP1 belongs 
to the ABC drug transporter family, included with seven 
known members (MRP1 to MRP7), which all diﬀ  er in 
tissue distribution and drug transport speciﬁ  city [33]. As 
determined by RT-PCR, MRP1 is expressed in nearly all 
breast cancers (and in approximately one-half of normal 
breast tissues) [25]. Th   is protein confers an MDR pheno-
type similar to, but distinct from, that associated with 
P-gp. MRP1 mediates resistance to agents such as vinca 
alkaloids, anthracyclines, and high-dose metho  trexate, 
but not to paclitaxel or mitoxantrone. Some studies 
suggest that MRP1 expression correlates with poor sur-
vival in patients with early-stage disease who received 
chemo  therapy, although a causal relationship is not clear 
[34].
Another ABC membrane transporter that may play a 
role in drug resistance is breast cancer resistance protein, 
since it is involved with the eﬄ     ux of various chemo-
therapeutics such as mitoxantrone, anthracyclines, 
methotrexate, and topoisomerase I inhibitors [35]. 
Resistance mediated by breast cancer resistance protein 
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resistance. Th  is transporter may be a marker for tumor 
stem cells and appears to protect against hypoxia [36,37].
Modifi  cation of drug target
Microtubules are essential components of the cyto-
skeleton and mitotic apparatus. Th   ey are assembled from 
α-tubulin and β-tubulin heterodimers, along with other 
proteins such as microtubule-associated proteins. 
Microtubule-targeting agents both inhibit microtubule 
polymerization and destabilize microtubules (such as 
vinca alkaloids), or they promote their polymerization 
and stabilization (for example, taxanes) [38]. Paclitaxel is 
known to bind to βIII-tubulin, which is one of the six 
known β-tubulin isotypes. Binding disrupts the micro-
tubule dynamics by stabilizing microtubules and induc-
ing microtubule bundles, thereby inhibiting cell division 
and triggering apoptosis [38].
Altered expression of β-tubulin isotypes is found in 
many cancer cell lines and xenografts resistant to micro-
tubule inhibitors, and this may be associated with the 
primary or acquired resistance to tubulin-binding agents 
observed clinically in many tumors (alterations in tubulin 
and associated proteins can aﬀ   ect the microtubule 
structure and function, and have been implicated in drug 
resistance; see Table 2) [39-47]. In vitro, the overexpression 
of the βIII subunit induces paclitaxel resistance, possibly 
by decreasing paclitaxel’s binding to βIII-tubulin and 
disrup  ting the microtubule dynamics [42]. Th  is  phenotype 
was seen in a leukemia cell line that was resistant to vin-
blastine, which was also cross-resistant to other vinca 
alkaloids and paclitaxel [48]. Other studies have also 
observed altered expression levels of tubulin or βIII iso-
forms that are associated with taxane resistance [40,41]. 
Additionally, several β-tubulin mutations have been 
characterized that result in drug resistance [43-45], which is 
probably due to alterations aﬀ  ecting the drug-binding sites. 
Owing to the confounding presence of tubulin pseudogenes, 
however, the clinical signiﬁ   cance of these mutations is 
unclear [49]. Changes in microtubule-associated proteins, 
such as microtubule-associated protein-4 and tau, can also 
aﬀ  ect the microtubule dynamics and modulate sensitivity 
to taxanes and vincas [46,47].
Clinically, βIII overexpression may serve as a surrogate 
for paclitaxel resistance in advanced breast cancer [50]. 
In breast cancer patients who are treated with ﬁ  rst-line 
paclitaxel, high βIII-tubulin expression correlated with 
disease progression [51]; similar results were seen in 
paclitaxel-resistant ovarian cancer [52].
DNA repair and cellular damage
In addition to P-gp and β-tubulin alterations, other 
mechanisms have been implicated in breast cancer drug 
resistance. Alterations in enzymes that are involved in 
DNA repair or that aﬀ  ect drug sensitivity can also aﬀ  ect 
drug resistance. Topoisomerase II is a critical enzyme 
that is involved in DNA replication and repair, in which 
reduced topoisomerase II expression or function can 
contribute to resistance to agents such as anthracyclines 
and epipodophyllotoxins [7,53]. Th   e loss of DNA-
mismatch repair activity – which mediates damage repair 
from many drugs including alkylating agents, platinum 
com  pounds, and anthracyclines – has also been impli-
cated in drug resistance [54]. In breast cancer, altered 
DNA-mismatch repair is associated with micro  satellite 
instability. Th  e loss of function of the DNA-mismatch 
repair proteins MSH2 and MLH1 resulted in resistance 
to the topoisomerase II inhibitors epirubicin, doxo-
rubicin, and mitoxantrone, but not to taxanes [55]. Th  e 
reduced expression of MLH1, following neoadjuvant 
chemotherapy for node-positive breast cancer, predicted 
poor disease-free survival [56], and in a study of sporadic 
invasive ductal carcinoma it was associated with 
resistance to the adjuvant cyclophosphamide, metho-
trexate, and ﬂ   uorouracil [57]. In general, the loss of 
hetero  zygosity or microsatellite instability can contribute 
Table 1. Mechanisms of drug resistance in breast cancer [24,25]
Class of resistance  Drug examples
Drug transport/sequestration  ABC transporters: P-glycoprotein, multidrug-resistant protein 1 (breast cancer resistance protein)
Modifi  cation of drug target (qualitative and quantitative)  Dihydrofolate reductase, epidermal growth factor receptor; C-KIT mutations; tubulin
DNA repair/genomic instability  Mismatch repair proteins; caspases, PTEN; p27; microsatellite instability, loss of heterozygosity, 
  topoisomerase I, topoisomerase II
Regulators of apoptosis  p53; PTEN; Bcl-2, Bcl-x
Drug metabolism/inactivation  Cytochrome P450; glutathione S-transferase; aldehyde dehydrogenase
ABC, ATP-binding cassette; PTEN, phosphatase and tensin homolog deleted on chromosome 10.
Table 2. Role of β-tubulin in drug resistance
Altered expression of β-tubulin isotypes [41,42] 
Overexpression of the βIII-tubulin subunit [40,43] 
β-Tubulin mutations aff  ecting microtubule stability and the binding of 
microtubule inhibitors [44-46] 
Changes in microtubule-associated proteins (for example, tau and 
microtubule-associated protein-4) [47,48] 
Post-translational modifi  cations of tubulin (for example, acetylation) [40] 
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resistance to certain regimens, such as epirubicin–
cyclophosphamide-based chemotherapy [58].
Apoptosis
In addition to DNA-mismatch repair, alterations regu-
lating cellular damage can contribute to drug resistance. 
Th  e levels of the thiol protease caspase-3, a key 
mediator of apoptosis, were found to be signiﬁ  cantly 
higher in breast cancer compared with normal tissue 
[59]. Th  e expression of a caspase-3s splice variant was 
also higher in breast carcinomas compared with 
nontumor tissue, and increased levels were correlated 
with resistance to cyclophosphamide-containing 
chemo therapy  [60].
MDR can arise from a failure of the cells to undergo 
apoptosis following DNA damage or other cellular injury. 
Mutations in the p53 tumor suppressor gene (which 
regulates apoptosis) are found in most human breast 
cancer cell lines [61], and certain mutations have been 
linked to de novo resistance to doxorubicin and early 
relapse in breast cancer [62]. In one study, p53 mutations 
were a strong prognostic factor for survival in patients 
with node-positive breast cancer who were administered 
adjuvant cyclophosphamide, methotrexate, and ﬂ  uorour-
acil, which may therefore predict resistance to such 
therapy [63]. Alterations in other genes regulating the 
apoptotic pathway, such as bcl-2  and  bcl-x, may also 
promote resis  tance to tubulin inhibitors [64]. Th  e  tumor 
suppressors phosphatase and tensin homolog deleted on 
chromosome 10 and p27 both regulate apoptosis, and the 
decreased expression of these proteins has been proposed 
to aﬀ  ect the response to trastuzumab [65] and resistance 
to chemotherapy [66], respectively.
Drug inactivation/detoxifi  cation
Other enzymes may aﬀ  ect breast cancer drug resistance, 
including those regulating drug inactivation or detoxiﬁ  c-
ation. Isoforms of aldehyde dehydrogenase, such as 
ALDH1A1 and ALDH3A1, can catalyze the detoxiﬁ  cation 
of cyclophosphamide and may therefore reduce 
sensitivity to this agent. Higher levels of ALDH3A1 have 
been found in breast cancer cells compared with normal 
tissues [67]. Moreover, the cellular levels of ALDH1A1 
(but not ALDH3A1) were signiﬁ  cantly higher in those 
metastatic tumors that did not respond to cyclo-
phosphamide-based regimens, when compared with 
tumors that were sensitive. Glutathione and glutathione 
S-transferase are involved in the detoxiﬁ  cation  of 
alkylating agents and cisplatin, so the modulation of their 
activity might aﬀ  ect the resistance to these compounds 
[68]. Cytochrome p450 is another enzyme that could be 
involved in resistance in taxanes. Polymorphisms in 
CYP3A4 and CYP2C8 associated with greater basal 
enzymatic activity lead to reduced plasma concentrations 
of the active drug [69].
Capecitabine
Capecitabine (ﬂ  uoropyrimidine carbamate) is rationally 
designed to generate ﬂ  uorouracil preferentially in tumor 
tissue and to mimic continuous infusion of ﬂ  uorouracil. 
Capecitabine is hydrolyzed in the liver by the enzyme 
carboxylesterase to produce 5΄-deoxy-5-ﬂ  uorocytidine, is 
then deaminated on its pyrimidine ring to produce 
5΄-deoxy-5-ﬂ   uorouridine by the enzyme cytidine 
deaminase, located mainly in hepatic and neoplastic 
tissue, and ﬁ   nally thymidine phosphorylase produces 
activation of 5΄-deoxy-5-ﬂ  uorouridine to ﬂ  uorouracil in 
tumor cells, thus minimizing systemic exposure to 
ﬂ  uorouracil [70].
Nowadays, capecitabine is the agent most evaluated in 
patients treated with taxanes. Clinical evidence supports 
the use of capecitabine in patients with MBC who have 
been previously exposed to taxanes. Th  e ﬁ   rst trial to 
evaluate the eﬃ   cacy and safety of capecitabine (twice-
daily oral 2,510  mg/m2/day for 2  weeks followed by a 
1-week rest and repeated in 3-week cycles) on 162 
patients with paclitaxel refractory MBC observed an 
overall response rate of 20% (95% conﬁ  dence  interval 
(CI), 14 to 28%) [71]. Diarrhea (14%) and hand–foot 
syndrome (10%) were the only treatment-related adverse 
events that occurred with grade 3 or grade 4 intensity in 
more than 10% of patients [71]. In a posterior phase II 
trial with 74 patients, an overall response rate of 26%, a 
median survival of 12.2 months, a median duration of 
response of 8.3 months, and a median time to disease 
progression of 3.2 months were observed [8]. With regard 
to the safety, treatment was well tolerated and the only 
grade 3 treatment-related adverse events reported in 
≥10% of patients were hand–foot syndrome (22%), 
diarrhea (16%), and stomatitis (12%) [8]. Other trials have 
also proven the eﬃ   cacy of capecitabine [9,10].
Epothilones
Given the clinical signiﬁ  cance of drug resistance found in 
most tumor cells and the challenges this presents for 
cancer therapy, new agents with novel mechanisms of 
action are needed. Epothilones represent a new class of 
microtubule inhibitors that have shown promising 
activity in MDR tumor cells, and have therefore been 
explored for the treatment of drug-resistant MBC.
Epothilones are a family of naturally occurring cyto-
toxic macrolides that inhibit microtubule function. 
Epothilones A and B, which are two major fermentation 
products originally isolated from the broth of the 
myxobacterium  Sorangium cellulosum, were found to 
stabilize polymerized microtubules and therefore to 
inhibit depolymerization [72,73]. Th  e epothilones are 
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may have a distinct mechanism of action [3]. Structural 
analyses indicate that epothilones may bind at or near the 
paclitaxel binding site on the β-tubulin protein [74-76]. 
In contrast to taxanes, certain epothilone B analogs 
inhibit those drug-resistant cells that overexpress P-gp – 
suggesting these compounds may be eﬀ   ective for the 
treatment of drug-resistant tumors, including those with 
an MDR phenotype.
Ixabepilone
One of the most active epothilone analogs is the 
semisynthetic derivative ixabepilone, which has superior 
stability and water solubility compared with epothilone B 
[77]. Just as in paclitaxel, ixabepilone results in G2/M cell 
cycle arrest and subsequent apoptosis, yet its median 
inhibitory concentration value is approximately 1 log lower 
than this taxane [23]. Low nanomolar concen  tra  tions of 
ixabepilone exert broad antitumor activity in a variety of 
solid tumor cell lines, including breast carcinoma [22,23]. 
In contrast to paclitaxel, ixabepilone can bind to multiple 
isomers of β-tubulin, including the βIII isoform [78].
In vitro, ixabepilone inhibits the growth of several 
drug-resistant cell lines, including some that are resistant 
to paclitaxel (Table 3) [11,22,23,78-80]. Ixabepilone has 
low susceptibility to various drug resistance mechanisms, 
such as MDR overexpression [81], β-tubulin mutations 
[82], and the overexpression of the βIII-tubulin isotype 
[22,77,83]. Notably, ixabepilone has shown activity in 
breast cancers with primary and acquired taxane resis-
tance. Ixabepilone is not a good substrate for MDR and 
does not strongly induce P-gp expression (possibly 
because of the relatively ﬂ  exible structure of this com-
pound), which may in part account for its activity in 
drug-resistant tumors [11]. Ixabepilone is not only active 
against paclitaxel-sensitive xenografts, but also demon-
strates signiﬁ  cant activity with paclitaxel-resistant human 
tumor models including breast carcinoma, ovarian 
cancer, and colorectal cancer xenografts [22].
In addition to showing activity in breast cancer, 
ixabepilone has also shown activity against a variety of 
other solid tumors. Antitumor activity was noted in 
cancers that were heavily pretreated or refractory, includ-
ing platinum-refractory nonsmall-cell lung cancer [84]. 
Ixabepilone has demonstrated clinical activity in some 
patients with tumors that are considered chemotherapy 
resistant, such as renal cell carcinoma [85] and advanced 
pancreatic cancer [86]. In light of its activity in breast 
cancer, and particularly in drug-resistant tumors, the 
clinical activity of ixabepilone was evaluated in patients 
with drug-resistant MBC.
As discussed previously, alterations in β-tubulin expres-
sion (including the βIII isotype) are associated with 
clinical resistance to taxanes. In contrast to paclitaxel, 
ixabepilone can bind to βIII-tubulin-containing micro-
tubules, which are dynamically more unstable than βII-
tubulin-based microtubules [78]. In addition, ixabepilone 
is active in preclinical tumor models that are resistant to 
paclitaxel due to mutations in β-tubulin [22,43]. Together, 
these results suggest that ixabepilone is eﬀ  ective for the 
treatment of breast cancer that is resistant to taxanes and 
to other agents arising from a variety of mechanisms. 
Molecular mechanisms of resistance to ixabepilone are 
still unknown and there have been no studies with a 
representative number of patients, but is suggested that 
polymorphisms of the carboxyl terminus of class I 
β-tubulin could be linked to resistance [87].
Clinical evidence of effi   cacy of ixabepilone in drug-
resistant metastatic breast cancer
Four key clinical trials of ixabepilone in drug-resistant 
breast cancer have been conducted, including two studies 
with single-agent ixabepilone and two studies with 
ixabepilone combined with capecitabine (Table 4) 
[88-92]. Th   e results of these studies indicate that 
ixabepilone is active in patients with a pretreated disease, 
including tumors resistant to anthracyclines, taxanes, 
and capecitabine, and in patients with wide  spread 
metastatic disease.
Taxane-resistant MBC: Trial 009
Given its activity in taxane-resistant breast cancer 
models, ixabepilone was clinically evaluated in patients 
with MBC resistant to taxane therapy. An international, 
multicenter phase II trial evaluated single-agent ixabepi-
lone in patients with MBC who were previously treated 
with an anthracycline-based regimen and were resistant 
to a taxane [88]. Patients were eligible if they had 
progressed within 4  months of taxane therapy in the 
metastatic setting (6  months if treated with adjuvant 
therapy only) and had a taxane as their last chemotherapy 
regimen. Consequently, these tumors were highly resis-
tant to prior treatment with a microtubule-stabilizing 
agent. Forty-nine patients were administered ixabepilone 
40 mg/m2, infused over 3 hours, every 21 days for up to 
Table 3. Preclinical activity of ixabepilone in drug-resistant 
cancer
Active against numerous drug-resistant tumor cell lines, including human 
paclitaxel-resistant breast cancer cell lines and xenografts [23,76-78] 
Inhibitory activity in breast cancers with primary or acquired resistance 
[23,78] 
Low susceptibility to multiple mechanisms of drug resistance [23,76] 
Multidrug resistance overexpression: overexpression of the βIII-tubulin 
isotype
Poor substrate for multidrug resistance; does not strongly induce 
P-glycoprotein expression [12]
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rate (ORR) was the primary endpoint.
Most patients in this study had been treated with at 
least two prior chemotherapy regimens. All of the 
patients had received at least one prior taxane-containing 
regimen (31% had at least two regimens), and 98% of 
patients had a taxane-containing regimen as their most 
recent therapy in the metastatic setting. Th  is  population 
was highly refractory because 73% of the patients had 
progressed within 1 month of their last administered 
taxane dose.
Of the 49 patients eligible for eﬃ   cacy analysis, there 
were six responses (ORR 12%) with a median duration of 
response of 10.4 months. All of the responders had exten-
sive baseline disease and had failed multiple therapies. 
An additional 20 patients (41%) had stable disease as 
their best response. Th   e median time to progression was 
2.2 months (95% CI, 1.4 to 3.2 months), and the median 
survival was 7.9 months (95% CI, 6.1 to 14.5 months). 
Responses seen with ixabepilone in patients with taxane-
resistant MBC conﬁ  rm its clinical activity in this patient 
population and support its diﬀ  erential sensitivity to the 
mechanisms of resistance.
Anthracycline-resistant, taxane-resistant, and 
capecitabine-resistant MBC: Trial 081
Th   e largest phase II trial evaluated single-agent ixabepi-
lone in patients with heavily pretreated or locally 
advanced disease or MBC resistant to the three standard 
chemotherapeutics in this setting; that is, anthracyclines, 
Table 4. Clinical trials of ixabepilone in drug-resistant metastatic breast cancer
     Evaluable  for
Study Population  effi   cacy/enrolled  Pretreatment characteristics  Activity
Ixabepilone monotherapy     
  Trial 009, phase II  Resistant to taxane; prior   49/49  All had received ≥1 prior taxane-based regimen  ORR 12%; 41% stable disease
  [88]  treatment with anthracycline-    (31% had ≥2 regimens); 98% had a taxane-
   based  regimena    containing regimen as their most recent MBC   Median DOR 10.4 months
        therapy, and 73% had progressed within 1 month 
        of the last administered taxane dose  Median TTP 2.2 months 
          (95% CI, 1.4 to 3.2 months)
         Median OS 7.9 months 
          (95% CI, 6.1 to 14.5 months)
  Trial 081, phase II  Resistant to an anthracycline,   113/126  77% with visceral disease in liver and/or lung;   ORR 11.5%; 50% stable disease
  [89]  a taxane, and capecitabine    88% had completed ≥2 prior chemotherapy 
        regimens for MBC, 48% had ≥3 lines  Median DOR 5.7 months 
          (95% CI, 4.4 to 7.3 months)
         Median PFS 3.1 months 
          (95% CI, 2.7 to 4.2 months)
         Median OS 8.6 months 
          (95% CI, 6.9 to 11.1 months)
Ixabepilone/capecitabine combination
  Trial 031, phase II  Anthracycline-pretreated   50/62  72% had baseline visceral metastases, 43%   ORR 30%c; 32% stable disease
  [90]  or resistant and taxane-    had ≥2 prior chemotherapy regimens in the 
   resistantb    metastatic setting for MBC  Median time to response 
          6 weeks (range, 5 to 14 weeks)
         Median DOR 6.9 months 
          (95% CI, 4.3 to 9.7 months)
  Trial 046, phase III  Pretreated with or resistant   737/752  65% had ≥3 metastatic disease sites; 48% had  ORR 34.7% vs. 14.3%
  [92]  to anthracyclines and     received ≥1 prior regimen for MBC; 85% had 
    resistant to taxanesd    progressed on prior taxane therapy for   Median DOR 6.4 months vs. 
        metastatic disease  5.6 months
         Median PFS 5.8 months vs. 
          4.2 months; hazard ratio = 0.75 
          (95% CI, 0.64 to 0.88)e
MBC, metastatic breast cancer; ORR, overall response rate; DOR, duration of response; TTP, time to progression (months); CI, confi  dence interval; OS, overall 
survival; PFS, progression-free survival. aPatients had progressed within 4 months of taxane therapy (6 months, if adjuvant therapy only) and had a taxane as their 
last chemotherapy regimen. bPatients were ineligible if they had received more than three prior chemotherapy regimens for metastatic disease. cAll responders 
had extensive metastatic disease at baseline. dResistance to anthracycline and taxane is defi  ned as tumor progression during treatment or within 3 months of the 
last administered dose in the metastatic setting, or recurrence within 6 months in the neoadjuvant or adjuvant setting. This was subsequently revised to include 
recurrence within 4 months of the last administered dose in the metastatic setting or 12 months in an adjuvant setting. eP = 0.0003.
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class was deﬁ  ned as disease progression during therapy 
for MBC (≤8 weeks of the previous treatment) or disease 
recurrence within 6 months of adjuvant or neoadjuvant 
chemotherapy with anthracycline or taxane. Ixabepilone 
40 mg/m2 was administered as a 3-hour intravenous infu-
sion on day 1 of a 21-day cycle. Th   e primary study end-
point was the ORR.
Th  e patients in this study had signiﬁ  cant and wide-
spread baseline disease: visceral disease in the liver and/
or lung was present in 77% of patients, and more than 
40% had at least three target lesions. Th   e majority of the 
patients (88%) had completed at least two prior chemo-
therapy regimens for MBC, and 48% had at least three 
therapy lines; 15% and 30% of patients had at least one 
line of anthracycline therapy and taxane therapy, 
respectively. All but two treated patients had taxane-
resistant disease, while 38% had anthracycline-resistant 
tumors. Many had failed prior chemotherapy for MBC 
including vinorelbine (25%), gemcitabine (13%), and 
trastuzumab for HER2-positive disease (9%).
Of the 126 patients enrolled, 113 were evaluable for a 
response. As assessed independently, the ORR was 11.5% 
(all partial responses) with another 50% of the patients 
achieving stable disease as their best response. Tumor 
responses were durable, with a median duration of 
5.7 months (95% CI, 4.4 to 7.3 months); eight of the 13 
responders remained progression free for ≥6 months. 
Th   e median progression-free survival (PFS) was 
3.1 months (95% CI, 2.7 to 4.2 months), and the median 
overall survival was 8.6 months (95% CI, 6.9 to 
11.1  months). Ixabepilone monotherapy was therefore 
active in patients with diﬃ   cult-to-treat, advanced, highly 
refractory breast cancer who had failed to respond to 
prior chemotherapy. One should note that nine of the 12 
responders to ixabepilone had not responded to prior 
multiple lines of chemotherapy in the metastatic setting, 
including combination regimens.
Anthracycline-resistant and taxane-resistant MBC: Trial 031
Given the single-agent activity of ixabepilone in women 
previously treated with anthracyclines, taxanes, and 
capecitabine, and the need for more eﬀ  ective second-line 
MBC regimens, the combination of ixabepilone and 
capecitabine was evaluated in phase II and phase III 
trials. In the phase II study, patients previously treated 
with anthracyclines and taxanes were treated with 
ixabepilone in addition to capecitabine [90]. Sixty-two 
patients were administered ixabepilone 40 mg/m2, in-
fused over 3 hours on day 1, in addition to capecitabine 
2,000 mg/m2 on days 1 to 14, both given every 21 days. 
Patients were ineligible if they had received more than 
three prior chemotherapy regimens for metastatic 
disease.
Fifty patients were evaluable for a response: 72% had 
baseline visceral metastases, and 42% received at least 
two prior chemotherapy regimens for metastatic disease. 
Fifteen responses occurred (30% ORR), and stable disease 
was achieved in 32% of patients. All of the responders 
had extensive metastatic disease at baseline. Th  e  median 
time to response was 6 weeks (range, 5 to 14 weeks), with 
most responses occurring by the end of the second cycle. 
Th  e median duration of response was 6.9 months (95% 
CI, 4.3 to 9.7 months). Four of the 15 responses occurred 
in patients with estrogen receptor-negative, progesterone 
receptor-negative, and HER2-negative (triple-negative) 
breast cancer, suggesting such a regimen may be eﬀ  ective 
for patients with this treatment-resistant subtype [91]. 
Th   ese preliminary results indicated that the combination 
of ixabepilone and capecitabine is active in patients with 
anthracycline-resistant and taxane-resistant MBC.
Anthracycline-resistant and taxane-resistant MBC: Trial 046
Th   ese encouraging phase II results led to an international, 
randomized, open-label phase III trial that compared 
ixabepilone plus capecitabine with solely capecitabine 
administration in patients with locally advanced or MBC 
pretreated with or resistant to anthracyclines and taxanes 
[92]. Patients were treated with ixabepilone 40 mg/m2, 
administered as a 3-hour infusion on day 1 of a 21-day 
cycle, plus cape  citabine 2,000 mg/m2 on days 1 to 14 of a 
21-day cycle. Th   ose patients on capecitabine alone were 
administered a dose of 2,500 mg/m2 on days 1 to 14 of a 
21-day cycle. Th  e primary endpoint was PFS. Th  e 
patients enrolled in this study (n = 752) had widespread 
disease and were heavily pretreated with chemotherapy. 
Most patients (65%) had at least three metastatic disease 
sites, and nearly one-half had received at least two prior 
regimens for metastatic disease. Th   e majority of patients 
(85%) had progressed on prior taxane therapy for MBC.
Th  e trial results demonstrated that PFS signiﬁ  cantly 
improved for patients treated with ixabepilone plus 
capecitabine compared with capecitabine alone (hazard 
ratio, 0.75; 95% CI, 0.64 to 0.88; P  = 0.0003), in turn 
reﬂ  ect  ing a 25% reduction in the estimated risk of disease 
progression (Figure 1). Median PFS increased by 40% 
with the combination (5.8 months vs. 4.2 months). Subset 
analyses indicated that the PFS beneﬁ  t occurred across 
subgroups. Th  e ORR also signiﬁ  cantly increased in the 
ixabepilone/capecitabine arm (35%; P < 0.0001) com  pared 
with capecitabine alone (14%); stable disease occurred in 
41% and 46% of patients, respectively. Th  e combination 
regimen demonstrated activity in triple-negative disease, 
conﬁ  rming the activity observed in this subgroup in the 
phase II trial. Mature overall survival data are anticipated 
within several months. Th  e most frequent grade 3/4 
adverse events in the ixabepilone plus capecitabine group 
were peripheral sensory neuropathy (with a median onset 
Rivera and Gomez Breast Cancer Research 2010, 12(Suppl 2):S2
http://breast-cancer-research.com/supplements/12/S2/S2
Page 7 of 12of four cycles), hand–foot syndrome, fatigue, myalgia, 
asthenia, and diarrhea; while the most frequent grade 3/4 
adverse events in the capecitabine group were hand–foot 
syndrome and diarrhea, but with incidences similar to 
those for the combination arm. Th   e incidence of adverse 
events commonly associated with capecitabine, such as 
hand–foot syndrome, were not exacerbated by the 
addition of ixabepilone.
Other metastatic breast cancer patient populations
In addition to its eﬃ   cacy in breast cancer resistant to 
chemotherapy, ixabepilone may also be eﬀ  ective for the 
treatment of other diﬃ   cult-to-treat populations. A pros-
pective subset analysis of the above phase III trial 
evaluated the response in HER2-positive patients who 
had been pretreated with or were resistant to anthra-
cyclines and taxanes, and who had progressed on trastu-
zu  mab [93]. Th  e combination of ixabepilone and cape-
cita bine  signiﬁ  cantly prolonged median PFS (5.3 months 
vs. 4.1 months) and the ORR (31% vs. 8%) compared with 
capecitabine monotherapy, which is similar to the beneﬁ  t 
observed in the overall population.
In a phase II trial, ixabepilone was combined with 
trastuzumab and carboplatin in patients with HER2-
positive MBC [94]. Of the 57 patients evaluable for a 
response, two had complete responses (3.5%), 22 had 
partial responses (38.6%), and 13 had stable disease for 
>6 months (22.8%); the median PFS was 8 months. A second 
prospectively deﬁ   ned subgroup analysis of the phase III 
study evaluated the combination regimen in patients with 
anthracycline-pretreated or anthracycline-resistant MBC 
whose tumors were estrogen receptor-negative  [95]. 
Ixabepilone plus capecitabine resulted in a median PFS of 
4.4 months (95% CI, 4.1 to 5.6) versus 2.8 months (95% CI, 
2.1 to 3.4) with capecitabine alone, and in a threefold 
increase of ORR (30% vs. 10%). Th  ese data suggest that 
ixabepilone combined with capecitabine may be eﬀ  ective 
for the treatment of various MBC patient populations with 
a poor prognosis and limited treatment options.
Toxicity
Ixabepilone is associated with a generally manageable 
safety proﬁ  le. Th   e toxicities associated with single-agent 
ixabepilone therapy are usually of a low grade and are 
comparable with those from other cytotoxic agents 
commonly used for breast cancer. In the four trials 
reported in the present review, the most common 
hematologic toxicity was myelo  suppression, primarily 
neutropenia. Grade 3/4 neutro  penia occurred in 53% of 
patients resistant to taxanes and in 54% of those resistant 
to anthracyclines, taxanes, and capecitabine. Grade 3/4 
leukopenia was ob  served in 2% of taxane-resistant 
patients and in 49% of taxane-resistant, anthracycline-
resistant, and capecitabine-resistant patients. Febrile 
neutropenia was rare [88,89]. Similar to other micro-
tubule inhibitors, neuropathy was one of the most 
frequent treatment-related adverse events occurring with 
ixabepilone. Th   is was usually mild to moderate in severity 
and generally resolved after dose adjustments were made. 
Peripheral sensory neuropathy was the most frequent 
grade 3/4 treatment-emergent adverse event (12 to 14%). 
Th  is toxicity was usually reversible, with resolution to 
grade 1 or baseline within a few weeks in the vast 
majority of patients. Th  e frequency and severity of this 
toxicity with ixabepilone was comparable with that 
observed with other microtubule inhibitors (2 to 32%) 
[96-99]. Th   e combination of ixabepilone and capecitabine 
was well tolerated, with minimally overlapping toxicities. 
Apart from peripheral neuropathy, there was no 
worsening of capecitabine-associated toxicities (for 
example, hand–foot syndrome, fatigue, and vomiting) 
with the combi  nation regimen.
New drugs and the future of the treatment of 
metastatic breast cancer resistant to paclitaxel
While ixabepilone is being evaluated in combination with 
other drugs, new drugs are currently being tested and 
have the potential to become standard treatments in this 
MBC setting. Albumin bound paclitaxel (nab-paclitaxel) 
has been studied in a phase II study of weekly albumin-
bound paclitaxel for patients with MBC heavily 
pretreated with taxanes. Response rates were 14% and 
16% for the 100  mg/m2 and 125  mg/m2 cohorts, 
respectively; an additional 12% and 21% of patients, 
respectively, had stable disease with an acceptable 
toxicity proﬁ  le [100].
Larotaxel is a semisynthetic taxoid that has shown 
preclinical and clinical activity against taxane-resistant 
Figure 1. Progression-free survival for patients treated with 
ixabepilone plus capecitabine. Kaplan–Meier progression-free 
survival curve from a phase III trial of ixabepilone plus capecitabine 
for metastatic breast cancer patients progressing after anthracycline 
and taxane treatment [88]. Reprinted with permission from Journal of 
Clinical Oncology.
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In a study of larotaxel in combination with trastuzumab 
in patients with HER2-positive MBC, 42.3% of conﬁ  rmed 
partial responses were achieved with a manageable 
toxicity [101]. Another taxoid currently evaluated in 
taxane-resistant tumors is cabazi  taxel. Although 
cabazitaxel has not been evaluated in breast cancer, 
results on a phase III prostate cancer are available [102].
Poly(ADP ribose) polymerase inhibitors are one group 
of drugs with great potential in resistant breast cancer, 
especially triple-negative and BRCA-deﬁ  cient  breast 
cancer. A phase II study of olaparib in conﬁ  rmed BRCA1/
BRCA2 carriers with advanced refractory breast cancer 
showed an ORR of 38% [103]. Other poly(ADP ribose) 
polymerase inhibitors being evaluated include veliparib 
in combination with temozolamide, results for which will 
be available in the near future [104].
Conclusion
Drug resistance (primary or acquired) is a leading cause 
of treatment failure in patients with cancer, especially 
MBC. Patients with advanced or MBC commonly develop 
disease resistance to chemotherapy and even biologic 
therapies such as trastuzumab, leaving few eﬀ  ective treat-
ment options. Th   e occurrence of MDR disease in many 
patients with advanced breast cancer due to the 
overexpression of βIII-tubulin isotype or drug trans-
porters, such as P-gp, demands new approaches. Conse-
quently, there is a signiﬁ  cant need for novel agents that 
are eﬀ  ective in drug-resistant tumors with mechanisms 
of action that are diﬀ   erent from the available 
chemo therapeutics.
Th  e epothilone B analog ixabepilone demonstrates 
signiﬁ  cant antitumor activity against a variety of tumor 
cells with primary or acquired drug resistance, including 
MDR. Ixabepilone is less susceptible to the common 
mechanisms of drug resistance, particularly tubulin 
mutations, compared with taxanes and other traditional 
chemotherapy. Clinical trials demonstrate single-agent 
ixabepilone to be active in MBC patients with highly 
resistant or refractory disease who have a signiﬁ  cant 
tumor burden. Antitumor activity was observed in those 
patients who have had extensive prior therapy with 
anthracyclines, taxanes, and/or capecitabine. Ixabepilone 
toxicity was manageable and comparable with other 
commonly used chemotherapeutics for MBC. In combi-
nation regimens, ixabepilone plus capecitabine resulted 
in greater activity compared with capecitabine alone in a 
taxane-resistant population, without signiﬁ  cantly 
increas  ing toxicity. Ixabepilone has been approved by the 
US Food and Drug Administration for use in combination 
with capecitabine for the treatment of locally advanced 
breast cancer or MBC after the failure of an anthracycline 
and a taxane, and as monotherapy after the failure of an 
anthracycline, a taxane, and capecitabine. A previous 
publication suggests that the cost-eﬀ  ectiveness  ratio 
could be higher for addition of ixabepilone to 
capecitabine treatment [105].
Th   e potential of ixabepilone in patients with early-stage 
breast cancer is currently under evaluation. Given the 
clinical impact of drug resistance in breast cancer and 
other malignancies, new agents are clearly needed with 
diﬀ   erential sensitivity to the various mechanisms of 
tumor resistance compared with the standard chemo-
therapy drugs. Increased application of pharmaco-
genomics may also allow for the identiﬁ  cation of patients 
with, or at increased risk for, drug resistance as well as 
those who are most likely to beneﬁ  t from the treatment.
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